These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 25297751

  • 21. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome.
    Silverman LR, Mufti GJ.
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S12-23. PubMed ID: 16341236
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Targeting DNA methylation.
    Issa JP, Kantarjian HM.
    Clin Cancer Res; 2009 Jun 15; 15(12):3938-46. PubMed ID: 19509174
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?
    Steensma DP.
    Best Pract Res Clin Haematol; 2012 Dec 15; 25(4):443-51. PubMed ID: 23200541
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Inhibition of dna methylation by 5-aza-2'-deoxycytidine correlates with induction of K562 cells differentiation.
    Fabianowska-Majewska K, Wyczechowska D, Czyz M.
    Adv Exp Med Biol; 2000 Dec 15; 486():343-7. PubMed ID: 11783512
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes.
    Steensma DP, Stone RM.
    Hematol Oncol Clin North Am; 2010 Apr 15; 24(2):389-406. PubMed ID: 20359633
    [Abstract] [Full Text] [Related]

  • 33. [Pharmacological profiles and clinical roles of 5-azacitidine (Vidaza(®) for injection 100 mg) for the treatment of myelodysplastic syndrome (MDS)].
    Takahashi Y, Kimura S, Okano M.
    Nihon Yakurigaku Zasshi; 2012 Nov 15; 140(5):235-43. PubMed ID: 23138323
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Life after hypomethylating agents in myelodysplastic syndrome: new strategies.
    Santini V.
    Curr Opin Hematol; 2015 Mar 15; 22(2):155-62. PubMed ID: 25603477
    [Abstract] [Full Text] [Related]

  • 39. Utility of DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromes.
    Tohyama K.
    Curr Pharm Des; 2012 Mar 15; 18(22):3190-7. PubMed ID: 22571698
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.